Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease

Thrombosis and Haemostasis

Volumn 85, Issue 4, 2001, Pages 667-670

  Van Thiel, D H ^a   George, M ^a   Fareed, J ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Coagulopathy; Disseminated intravascular coagulopathy (DIC); Fibrinolysis; Liver disease; TAFI

Indexed keywords

BLOOD CLOTTING FACTOR; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOLYTIC FACTOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; REGULATORY MECHANISM;

EID: 0035073313     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615651     Document Type: Article

References (11)

1. Thrombin activation and increased fibrinolysis in patients with chronic liver disease
2. Coagulopathies of liver disease
3. Coagulation defects in liver disease
4. Coagulation abnormalities in liver disease
5. Coagulation activation in liver diseases
6. Thrombin activation and increased fibinolysis in patients with chronic liver disease
7. Disseminated intravascular coagulation after hepatic resection
8. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease
9. TAFI
10. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukemia
11. Plasma TAFI antigen variation in healthy subjects